TB-500
Thymosin Beta-4
Systemic tissue repair and anti-inflammatory recovery for athletes and injury rehabilitation.
Medical Disclaimer: The information on this page is for educational purposes only and does not constitute medical advice. Peptides discussed may be research compounds not approved for human use. Always consult a qualified healthcare provider before starting any peptide protocol. Read our full disclaimer →
Quick Reference
| Peptide Class | Thymosin peptide |
| Half-Life | ~3–4 days |
| Administration | Subcutaneous injection, Intramuscular injection |
| Typical Dosage | 2–2.5 mg twice weekly (loading), 2–2.5 mg weekly (maintenance) |
| Cycle Length | 4–6 weeks loading, then maintenance |
| Evidence Level | Moderate Preclinical / Emerging Human |
| Legal Status | Research compound — not FDA-approved for human use |
| Approximate Cost | $40–$90 per vial |
How TB-500 Works
Promotes cell migration and differentiation via actin regulation; reduces inflammatory cytokines systemically.
TB-500 (Thymosin Beta-4) is a naturally occurring peptide found in high concentrations in blood platelets and wound fluid. Its primary mechanism involves the regulation of actin — the structural protein that governs cell shape, migration, and division. By sequestering G-actin monomers, TB-500 promotes the migration of endothelial cells and keratinocytes to injury sites, accelerating tissue repair. It also downregulates pro-inflammatory cytokines including TNF-α and IL-1β, providing systemic anti-inflammatory effects that distinguish it from more localized healing peptides like BPC-157.
Evidence Base
Preclinical Evidence
Animal studies demonstrate accelerated healing of cardiac tissue after myocardial infarction, improved recovery from muscle tears, and enhanced wound closure. TB-500 has shown particular promise in cardiac repair models, where it promotes cardiomyocyte survival and angiogenesis following ischemic injury.
Human Evidence
Limited human data available. Phase I/II trials have been conducted for cardiac applications (post-MI recovery), showing acceptable safety profiles. No large-scale trials for musculoskeletal applications have been completed. All athletic and biohacking use is off-label.
Anecdotal Evidence
Athletes report TB-500 as particularly effective for systemic muscle injuries, widespread inflammation, and recovery from high-volume training. It is frequently compared to BPC-157, with the consensus being that TB-500 is better for systemic, diffuse injuries while BPC-157 excels at localized tendon and gut healing.
Key PubMed References:
Safety Profile
Side Effects
Generally well-tolerated. Reported side effects include mild fatigue, headache, and injection-site reactions. Some users report temporary nausea at higher loading doses.
Contraindications
Caution in individuals with active malignancy due to theoretical pro-angiogenic effects. Not recommended during pregnancy. Avoid concurrent use with other peptides that strongly promote angiogenesis without medical supervision.
PeptidePilot Assessment
TB-500 is PeptidePilot's preferred recommendation for users with systemic musculoskeletal injuries, widespread inflammation, or high-volume athletic training loads. In our algorithm, it scores highest for users who report multiple injury sites, significant post-training inflammation, or endurance training backgrounds. It is frequently recommended alongside BPC-157 in our Recovery Stack for users with complex injury profiles.
📊 14% of PeptidePilot users focused on injury recovery receive TB-500 as their top match
Frequently Asked Questions
Explore More Peptides
The most researched healing peptide for joints, tendons, and gut tissue.
The cleanest growth hormone secretagogue for muscle growth, fat loss, and sleep quality.
Extended-release GHRH analogue that amplifies and sustains growth hormone pulses.
The clinically established GHRH analogue with the longest safety record in anti-aging medicine.
The most clinically validated peptide for weight loss and metabolic health.
The next-generation dual-agonist delivering superior weight loss to Semaglutide in clinical trials.